Smith & Nephew plc (NYSE:SNN) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $42.00.
Several brokerages have commented on SNN. Canaccord Genuity began coverage on Smith & Nephew in a research report on Wednesday, October 11th. They issued a “buy” rating and a $42.00 price target on the stock. Zacks Investment Research downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. Finally, Morgan Stanley downgraded Smith & Nephew from an “overweight” rating to an “equal weight” rating in a research report on Monday, December 11th.
Shares of Smith & Nephew (SNN) traded down $0.25 during midday trading on Friday, reaching $34.58. The company’s stock had a trading volume of 336,800 shares, compared to its average volume of 604,033. The company has a current ratio of 2.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Smith & Nephew has a 52 week low of $29.76 and a 52 week high of $40.43.
Smith & Nephew Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.